NewAmsterdam Pharma Company (NAMS) Financial Statements & Analysis

NewAmsterdam Pharma Company (NAMS) Income Statement

NewAmsterdam Pharma Company reported revenue of $22.50M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 50.6% from $45.56M a year earlier. NewAmsterdam Pharma Company posted a net loss of $203.82M, compared with a net loss of $245.78M a year earlier. Gross margin was 100.0% and operating margin -1002.9%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $3.70M, down 80.7% from the same quarter a year earlier.

NewAmsterdam Pharma Company Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

NewAmsterdam Pharma Company N.V. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	22.50	45.56	14.09	102.69	102.69	0.00	0.00
Cost of Revenue	0.06	0.00	0.00	0.00	-	0.00	0.00
Gross Profit	22.50	45.56	14.09	102.69	102.69	0.00	0.00
Operating Expenses
Research & Development	141.83	151.41	159.42	86.74	86.74	28.97	4.94
Selling, General & Administrative	106.35	70.45	37.63	19.51	19.51	5.68	1.69
Operating Expenses	248.19	-226.00	197.06	106.25	-49.11	34.65	6.63
Operating Income	-225.68	-180.44	-182.97	-3.56	-70.94	-34.65	-6.63
Other Income/Expense
Interest Income	27.59	16.88	11.28	0.00	0.01	0.01	0.00
Interest Expense	0.00	0.00	6.80	0.29	-0.29	0.41	0.00
Other Income/Expense	-5.73	-65.34	-5.23	-19.08	-11.06	-6.40	-0.39
Income
Income Before Tax	-203.82	-241.60	-176.91	-22.63	-22.63	-41.79	-7.02
Income Tax Expense	0.00	0.00	0.03	0.00	-	0.00	0.00
Net Income	-203.82	-245.78	-176.94	-22.63	-82.00	-41.79	-7.02
Net Income - Continuous Operations	-203.82	-241.60	-176.94	-22.63	-22.63	-41.79	-7.02
Net Income - Discontinued Operations	-	-	-	-	-	-	-
EBITDA	-225.46	-176.18	-182.92	-22.34	-3.55	-41.37	-6.63
EBIT	-225.68	-176.29	-182.97	-	-3.56	-41.37	-
Depreciation & Amortization	0.22	0.11	0.05	0.01	0.01	0.02	0.00
Earnings Per Share
Basic EPS	-2.00	-3.00	-2.00	-1.00	-1.00	-1.00	-
Diluted EPS	-2.00	-3.00	-2.00	-1.00	-1.00	-1.00	-
Basic Shares Outstanding	114.40	94.36	82.16	18.97	18.97	81.56	17.75
Diluted Shares Outstanding	114.40	94.36	82.16	18.97	18.97	81.56	17.75

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About NewAmsterdam Pharma Company Financial Statements

What was NewAmsterdam Pharma Company's revenue in fiscal 2025?

NewAmsterdam Pharma Company reported revenue of $22.50M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 50.6% from $45.56M a year earlier.

Is NewAmsterdam Pharma Company profitable?

No. NewAmsterdam Pharma Company reported a net loss of $203.82M in fiscal 2025. In fiscal 2024 it lost $245.78M.

What is NewAmsterdam Pharma Company's operating margin?

NewAmsterdam Pharma Company's operating income was −$225.68M on revenue of $22.50M in fiscal 2025, an operating margin of -1002.9%, compared with -396.0% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition